Dispenser with reservoir containing a drug of abuse

a technology of diamorphine and reservoir, which is applied in the field of formulations, dosage forms and delivery modes, can solve the problems of diamorphine abuse, less prevalent use of diamorphine for pain relief, and less prevalence of potentiation of abus

Inactive Publication Date: 2006-07-20
GW PHARMA LTD
View PDF11 Cites 58 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This gives the potential for abuse.
This oscillation produces a number of problems in homeostatic systems, which may also interact with endogenous opioids.
Diamorphine abuse is a major problem; however dependence in patients who are receiving diamorphine for the relief of pain is much less prevalent.
However the regime is expensive to run as a doctor has to be available daily to dispense the drugs and it is inconvenient for patients who have to travel to the doctor each day.
Problems associated with the current treatment of, in particular, diamorphine addicts include: Illicit supplies of heroin are of variable quantity and some may pose health hazards; Intravenous (iv) administration of heroin by injection opens up the possibility of infection and disease transmission through needle sharing or more seriously, death by overdose; and Whilst supervised administration of defined doses of diamorphine is a recognised strategy it requires input of healthcare professionals, time and counselling to be effective.
These doses, however, need to be difficult to divert per se, i.e. without achieving this end solely by the close supervision by health professionals.
Generally, however, the reservoir is for use with a dispenser and without which the contents of the reservoir may not be accessed (without breaking into the reservoir for example).
However, this is likely to be time consuming, and if text input is required, some further device such as lap top computer, PDA, or communications device can be connected to the base station 2 either physically or remotely.
Such an approach is not always desirable, or, indeed, convenient, and it may be particularly awkward for people with arthritis.
If however the same cartridge is inserted into another device that the cartridge has not been configured for, the cartridge will not authorise that dispense device.
The formulation of diamorphine for nasal sprays are initially formulated as dry mixtures since diamorphine is insufficiently stable in aqueous solution to be supplied as such.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dispenser with reservoir containing a drug of abuse
  • Dispenser with reservoir containing a drug of abuse
  • Dispenser with reservoir containing a drug of abuse

Examples

Experimental program
Comparison scheme
Effect test

example 2

Diamorphine Formulation for Nasal Delivery

[0126] A preparation for intranasal administration can be made as follows. The quantities given are sufficient to prepare a dispenser containing 100 dosage units each of which comprise either 10 or 20 mg of diamorphine hydrochloride.

CONSTITUENTABCDDiamorphine Hydrochloride1 g2 g1 g2 gCaffeine200 mg200 mg200 mg200 mgSodium Benzoate200 mg200 mg——Sodium Salicylate——200 mg200 mgWater (added prior to use)to 5 mlto 5 mlto 5 mlto 5 ml

[0127] In other words, where solutions A, B, C and D are used to generate 100 dosage units, each is of a volume of 50 μl and comprises 1 / 100 of the quantities listed in the table.

[0128] 5 ml of solution A contained in a manually operated nasal spray with a 50 μL dispenser delivers a dose of 10 mg of diamorphine hydrochloride. Solution B in a similar container will provide a unit dose of 20 mg.

[0129] The constituents of this mixture are stable in the dry state and in practice, quantities of the dry ingredients are...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to novel formulations, dosage forms and modes of delivery for treating patients addicted to a group of drugs which can result in dependence and misuse. The most serious drugs of addiction are cocaine, diamorphine (heroin), morphine and the synthetic opioids.

Description

FIELD OF THE INVENTION [0001] The present invention relates to novel formulations, dosage forms and modes of delivery for treating patients addicted to a group of drugs which can result in dependence and misuse. The most serious drugs of addiction are cocaine, diamorphine (heroin), morphine and the synthetic opioids. BACKGROUND DESCRIPTION [0002] The Misuse of Drugs Act 1971 prohibits certain activities in relation to “controlled drugs”. [0003] Controlled drugs are placed in one of three class categories: [0004] Class A includes: alfentanil, cocaine, dextromoramide, diamorphine (heroin), dipipanone, lysergide (LSD), methadone, methylenedioxymethamfetamine (MDMA, “ecstasy”), morphine, opium, pethidine, phencyclidine and class B substances when prepared for injection; [0005] Class B includes: oral amphetamines, barbiturates, cannabis, cannabis resin, codeine, ethylmorphine, glutethimide, pentazocine, phenmetrazine and pholcodine; and [0006] Class C includes: certain drugs related to a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G07F11/00A61J7/04A61M15/00A61P25/36
CPCA61J7/04A61J7/0481A61J2007/0418A61J2007/0445A61J2007/049A61M15/00A61M15/0065A61M15/009A61M2205/18A61M2205/3553A61M2205/3561A61M2205/3569A61M2205/3584A61M2205/3592A61M2205/52A61M2205/581A61M2205/6072A61M2205/8206A61M2205/8237A61M2209/086G07F17/0092A61M15/008A61J7/0418A61J7/0445A61J2205/70A61M15/0066A61P25/36
Inventor WHITTLE, BRIAN A.DAVE, RAJIVB
Owner GW PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products